YDES
YD Bio Limited Ordinary Shares
Biotechnology
Market Cap$22M
5Y Perf.-15.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
YDES vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.53B
5Y Perf.+10.2%
YDES vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | YDES | IMVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $22M | $5.53B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-3M | $-464M |
| Gross Margin | 30.4% | — |
| Operating Margin | -286.5% | — |
| Total Debt | $23K | $98K |
| Cash & Equiv. | $3M | $714M |
Quick Verdict: YDES vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: IMVT leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. YD Bio Limited Ordinary Shares is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
YDES
YD Bio Limited Ordinary Shares
The Income Pick
YDES is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 0.81
- Lower volatility, beta 0.81, Low D/E 0.3%, current ratio 13.18x
- Beta 0.81, current ratio 13.18x
Best for: income & stability and sleep-well-at-night
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 173.6% 10Y total return vs YDES's -56.1%
- 3.2% margin vs YDES's -276.6%
- +96.1% vs YDES's -56.1%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | YDES | 45.8% revenue growth vs IMVT's -21.3% |
| Quality / Margins | IMVT | 3.2% margin vs YDES's -276.6% |
| Stability / Safety | YDES | Beta 0.81 vs IMVT's 1.37 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | IMVT | +96.1% vs YDES's -56.1% |
| Efficiency (ROA) | IMVT | -44.1% ROA vs YDES's -100.8% |
YDES vs IMVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIMVTLAGGINGYDES
YDESYD Bio Limited Ordina…
1leads
IMVTImmunovant, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs YDESMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
IMVT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
YDES4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
IMVT6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
IMVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
YDES and IMVT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | YDESYD Bio Limited Or… | IMVTImmunovant, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$3M | -$487M |
| Net IncomeAfter-tax profit | -$3M | -$464M |
| Free Cash FlowCash after capex | -$1M | -$423M |
| Gross MarginGross profit ÷ Revenue | +30.4% | — |
| Operating MarginEBIT ÷ Revenue | -2.9% | — |
| Net MarginNet income ÷ Revenue | -2.8% | — |
| FCF MarginFCF ÷ Revenue | -9.3% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -116.0% | +19.7% |
IMVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — YDES and IMVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | YDESYD Bio Limited Or… | IMVTImmunovant, Inc. |
|---|---|---|
| Market CapShares × price | $22M | $5.5B |
| Enterprise ValueMkt cap + debt − cash | $19M | $4.8B |
| Trailing P/EPrice ÷ TTM EPS | -9.45x | -9.97x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 42.99x | — |
| Price / BookPrice ÷ Book value/share | 3.33x | 5.83x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — YDES and IMVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
YDES leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
YDES delivers a -42.7% return on equity — every $100 of shareholder capital generates $-43 in annual profit, vs $-47 for IMVT. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to YDES's 0.00x. On the Piotroski fundamental quality scale (0–9), YDES scores 3/9 vs IMVT's 2/9, reflecting mixed financial health.
| Metric | YDESYD Bio Limited Or… | IMVTImmunovant, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -42.7% | -47.1% |
| ROA (TTM)Return on assets | -100.8% | -44.1% |
| ROICReturn on invested capital | -63.3% | — |
| ROCEReturn on capital employed | -44.1% | -66.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | 0.00x | 0.00x |
| Net DebtTotal debt minus cash | -$3M | -$714M |
| Cash & Equiv.Liquid assets | $3M | $714M |
| Total DebtShort + long-term debt | $22,555 | $98,000 |
| Interest CoverageEBIT ÷ Interest expense | -1893.69x | — |
YDES leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $16,241 today (with dividends reinvested), compared to $4,395 for YDES. Over the past 12 months, IMVT leads with a +96.1% total return vs YDES's -56.1%. The 3-year compound annual growth rate (CAGR) favors IMVT at 12.1% vs YDES's -24.0% — a key indicator of consistent wealth creation.
| Metric | YDESYD Bio Limited Or… | IMVTImmunovant, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -55.9% | +5.1% |
| 1-Year ReturnPast 12 months | -56.1% | +96.1% |
| 3-Year ReturnCumulative with dividends | -56.1% | +40.9% |
| 5-Year ReturnCumulative with dividends | -56.1% | +62.4% |
| 10-Year ReturnCumulative with dividends | -56.1% | +173.6% |
| CAGR (3Y)Annualised 3-year return | -24.0% | +12.1% |
IMVT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — YDES and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
YDES is the less volatile stock with a 0.81 beta — it tends to amplify market swings less than IMVT's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 90.5% from its 52-week high vs YDES's 21.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | YDESYD Bio Limited Or… | IMVTImmunovant, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.81x | 1.37x |
| 52-Week HighHighest price in past year | $25.00 | $30.09 |
| 52-Week LowLowest price in past year | $4.73 | $13.36 |
| % of 52W HighCurrent price vs 52-week peak | +21.2% | +90.5% |
| RSI (14)Momentum oscillator 0–100 | 39.6 | 60.2 |
| Avg Volume (50D)Average daily shares traded | 20K | 1.4M |
Evenly matched — YDES and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | YDESYD Bio Limited Or… | IMVTImmunovant, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $45.50 |
| # AnalystsCovering analysts | — | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
IMVT leads in 2 of 6 categories (Income & Cash Flow, Total Returns). YDES leads in 1 (Profitability & Efficiency). 2 tied.
Best OverallImmunovant, Inc. (IMVT)Leads 2 of 6 categories
Loading custom metrics...
YDES vs IMVT: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is YDES or IMVT a better buy right now?
Analysts rate Immunovant, Inc.
(IMVT) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — YDES or IMVT?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +62. 4%, compared to -56. 1% for YD Bio Limited Ordinary Shares (YDES). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus YDES's -56. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — YDES or IMVT?
By beta (market sensitivity over 5 years), YD Bio Limited Ordinary Shares (YDES) is the lower-risk stock at 0.
81β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 69% more volatile than YDES relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 0% for YD Bio Limited Ordinary Shares — giving it more financial flexibility in a downturn.
04Which has better profit margins — YDES or IMVT?
Immunovant, Inc.
(IMVT) is the more profitable company, earning 0. 0% net margin versus -276. 6% for YD Bio Limited Ordinary Shares — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IMVT leads at 0. 0% versus -286. 5% for YDES. At the gross margin level — before operating expenses — YDES leads at 30. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — YDES or IMVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is YDES or IMVT better for a retirement portfolio?
For long-horizon retirement investors, YD Bio Limited Ordinary Shares (YDES) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
81)). Both have compounded well over 10 years (YDES: -56. 1%, IMVT: +173. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between YDES and IMVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: YDES is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.